Nice post Investorxc! I agree that spinning off Elto is a bad idea. Think about it - Our current market cap is $5.32 mil. If the market recognizes that Elto accounts for half of that market cap, theoretically our market cap would drop to $2.66 mil following the spinoff. While we all feel that we’re undervalued at the current price, it is what it is. Forget about retaining a stake in the Elto sub - Only Gerald will truly benefit, not retail AMBS shareholders. The Avant debacle is a perfect example of that and I view it (a potential spin-off of Elto) as nothing more than complicated financial engineering. Actually it’s quite simple. If you own a stake in 5 separate entities and three fail, you still have the other two. It’s like stock diversification but at a higher level - like solely owning the IBB vs. 5 separate biotech’s. When the biotech sector gets hit, the IBB goes down. When you own 5 separate stocks and the biotech market gets hit, not all are necessarily going to be down. Now figure that of those 5 stocks, most of the actual stock you own was issued at IPO or at significant discount and... Well let’s just say that in the case of AMBS spinning off our assets into subsidiary IPO’s, management would clearly benefit over the retail shareholder of the parent company.
I’ve said it before and I’ll say it again - We need partnerships and upfront $$$ with milestone $$$ to follow.
(1)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links